Trial Profile

Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 21 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nogapendekin alfa inbakicept (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms QUILT2.023
Sponsors Altor BioScience Corporation; ImmunityBio

16 Oct 2025 Planned End Date changed from 1 Apr 2026 to 31 Dec 2026.
16 Oct 2025 Planned primary completion date changed from 1 Oct 2025 to 31 Oct 2026.
09 Oct 2025 The protocol has been amended to addition in efficacy endpoint and modification in treatment arms.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com